Results 21 to 30 of about 16,563 (220)
Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
BMC Cancer, 2020 Background The evidence that albumin-bound paclitaxel (nab-paclitaxel) is safe and efficacious for the treatment of many types of malignant tumors is continuously increasing.
Zhichao Tian +7 more
doaj +1 more source
Therapeutic Advances in Medical Oncology, 2020 Background: The effectiveness of atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer (TNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on advanced TNBC from the US payer perspective. Methods: A Markov model
Bin Wu, Fei Ma
doaj +1 more source
Frontiers in Public Health, 2021 Purpose: The IMpassion130 trial demonstrated the efficacy of adding atezolizumab to paclitaxel for advanced or metastatic triple-negative breast cancer (TNBC).
Xiaoyan Liu +4 more
doaj +1 more source
Thoracic Cancer, 2020 Background Previous trials have suggested that elderly patients with non‐small‐cell lung cancer (NSCLC) could benefit from nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel). Real‐world data on the elderly Chinese population are lacking.
Shuhang Wang +12 more
doaj +1 more source
Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use [PDF]
Farmacia Hospitalaria, 2015 Objective: To evaluate the results obtained with the combined use of nab-paclitaxel and gemcitabine in the treatment of patients with metastatic pancreatic adenocarcinoma. Materials and methods: Retrospective observational study.
Elena Ferris Villanueva +5 more
doaj +1 more source
Translational Oncology, 2018 Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is
Md Sazzad Hassan +6 more
doaj +1 more source
Dermatology Practical & Conceptual, 2015 Background: Taxanes [paclitaxel, nab-paclitaxel (Abraxane, Celgene Corp, USA), and docetaxel]—used in the treatment of lung, breast, and head and neck cancers—have been associated with cutaneous adverse effects, including photodermatoses.
Bryce D. Beutler, Philip R. Cohen
doaj +1 more source
Journal of Experimental & Clinical Cancer Research, 2022 Background Chemoresistance is a main obstacle in gastric cancer (GC) treatment, but its molecular mechanism still needs to be elucidated. Here, we aim to reveal the underlying mechanisms of nanoparticle albumin-bound paclitaxel (nab-paclitaxel ...
Mengxuan Zhu +8 more
doaj +1 more source
First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report [PDF]
Case Reports in Oncology, 2017 Thymic carcinomas are rare malignant tumors, located in the anterior mediastinum. For the treatment of these carcinomas, several chemotherapy regimens have been suggested, including carboplatin plus paclitaxel. However, because of the rarity of these tumors, the standard chemotherapy regimen has not yet been established.
Kunihiko Funaishi +7 more
openaire +3 more sources
Качественная клиническая практика, 2020 Objective. To determine the pharmacoeconomical feasibility of using a combination of atezolizumab + nab-paclitaxel in the 1st line of therapy for locally advanced or metastatic triple negative breast cancer (TNBC) in adult PDL1 positive patients in the ...
A S Kolbin +4 more
doaj +1 more source